ShareTalk New Year Digest: 20 stocks to watch in Q1 202426 Dec 2023 21:02
Poolbeg Pharma (LON: POLB) Up 50% year-to-date, Poolbeg Pharma’s flagship POLB 001 has certainly captured the market’s attention as a potential therapy for Cytokine Release Syndrome, associated with cancer immunotherapies. But less discussed is the AI developments — the company’s artificial intelligence led programme has identified a number of promising RSV drug candidates for further analysis — and this could be just the start of a revolutionary clinical approach.